Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Your provider can review your progress, discuss side effect management, and help you decide whether adjusting your dose within the once-weekly framework, trying a different formulation, or exploring combination therapy makes sense for your goals
Its part of a class of drugs called GLP-1 receptor agonists (glucagon-like peptide-1), which mimic a hormone in your body that helps regulate blood sugar, insulin levels, and appetite
timeline spans roughly 2021 to 2024 FDA-approved GLP-1 options / Semaglutide 2.4 mg (Wegovy, approved June 2021) and tirzepatide 15 mg (Zepbound, approved November 2023) STEP-1 mean weight loss / 14.9% body-weight reduction at 68 weeks with semaglutide 2.4 mg vs
- C
The warning signs include declining gym performance, persistent muscle soreness, and a "softer" physical appearance despite weight loss
Table of Contents Why GLP-1 Medications Cause Bloating Glucagon-like peptide-1 (GLP-1) receptor agonists including semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Saxenda, Victoza) are increasingly prescribed for type 2 diabetes management and weight loss
